- Home
- PRLD vs SNTI Comparison
PRLD vs SNTI Comparison
Compare PRLD & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- SNTI
- Stock Information
- Founded
- PRLD 2016
- SNTI 2016
- Country
- PRLD United States
- SNTI United States
- Employees
- PRLD N/A
- SNTI N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- SNTI Health Care
- Exchange
- PRLD Nasdaq
- SNTI Nasdaq
- Market Cap
- PRLD 44.0M
- SNTI 39.6M
- IPO Year
- PRLD 2020
- SNTI N/A
- Fundamental
- Price
- PRLD $1.03
- SNTI $1.41
- Analyst Decision
- PRLD Strong Buy
- SNTI Strong Buy
- Analyst Count
- PRLD 3
- SNTI 2
- Target Price
- PRLD $4.00
- SNTI $8.50
- AVG Volume (30 Days)
- PRLD 231.3K
- SNTI 120.0K
- Earning Date
- PRLD 11-05-2025
- SNTI 11-13-2025
- Dividend Yield
- PRLD N/A
- SNTI N/A
- EPS Growth
- PRLD N/A
- SNTI N/A
- EPS
- PRLD N/A
- SNTI N/A
- Revenue
- PRLD $7,000,000.00
- SNTI N/A
- Revenue This Year
- PRLD N/A
- SNTI N/A
- Revenue Next Year
- PRLD N/A
- SNTI $150.00
- P/E Ratio
- PRLD N/A
- SNTI N/A
- Revenue Growth
- PRLD N/A
- SNTI N/A
- 52 Week Low
- PRLD $0.61
- SNTI $1.26
- 52 Week High
- PRLD $2.72
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- PRLD 45.61
- SNTI 40.09
- Support Level
- PRLD $1.03
- SNTI $1.33
- Resistance Level
- PRLD $1.26
- SNTI $1.42
- Average True Range (ATR)
- PRLD 0.11
- SNTI 0.07
- MACD
- PRLD -0.03
- SNTI 0.02
- Stochastic Oscillator
- PRLD 10.34
- SNTI 46.55
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.